Leukemia News and Research

RSS
Leukemia (Leukaemia) is a cancer of the blood cells. It is the most common type of blood cancer and affects 10 times as many adults as children. Most people diagnosed with leukemia are over 50 years old. No one knows why some people develop leukemia and others do not. However, scientists have identified some risk factors for the disease. Most people who have known risk factors do not get leukemia, while many who do get the disease have none of these risk factors. During the early stages of leukemia, there may be no symptoms. Many of the symptoms of leukemia don't become apparent until a large number of normal blood cells are crowded out by leukemia cells.
Pesticide use in agriculture may pose cancer risks similar to smoking

Pesticide use in agriculture may pose cancer risks similar to smoking

Breakthrough in acute myeloid leukemia treatment targets stem cells

Breakthrough in acute myeloid leukemia treatment targets stem cells

Unraveling the role of TAL1 and miR-146b-5p in T-cell acute lymphoblastic leukemia

Unraveling the role of TAL1 and miR-146b-5p in T-cell acute lymphoblastic leukemia

Researchers discover new target for treating diseases linked to T-cell leukemia virus type 1

Researchers discover new target for treating diseases linked to T-cell leukemia virus type 1

USC scientists transform B cells into cancer and HIV destroyers

USC scientists transform B cells into cancer and HIV destroyers

DDX41: A unique player in myeloid leukemogenesis

DDX41: A unique player in myeloid leukemogenesis

CD5 knockout using CRISPR boosts CAR T cell therapy efficacy

CD5 knockout using CRISPR boosts CAR T cell therapy efficacy

Novel therapy can improve the prognosis of relapsed/refractory acute myeloid leukemia

Novel therapy can improve the prognosis of relapsed/refractory acute myeloid leukemia

NYU Langone Health earns No. 1 spot in neurology and neurosurgery for the third straight year

NYU Langone Health earns No. 1 spot in neurology and neurosurgery for the third straight year

CD22-targeted CAR-T therapy shows promising results in relapsed large B-cell lymphoma

CD22-targeted CAR-T therapy shows promising results in relapsed large B-cell lymphoma

Novel Co-STAR cells show promise in targeting and eradicating cancer

Novel Co-STAR cells show promise in targeting and eradicating cancer

Scientists discover a molecular defect that promotes pathologic immune response in lupus

Scientists discover a molecular defect that promotes pathologic immune response in lupus

Fungal endophytes: A promising frontier for breast cancer treatment

Fungal endophytes: A promising frontier for breast cancer treatment

Novel antiviral protein SAMD9L blocks HIV-1 and other lentiviruses

Novel antiviral protein SAMD9L blocks HIV-1 and other lentiviruses

High ambient temperatures during pregnancy can have detrimental impact on offspring health

High ambient temperatures during pregnancy can have detrimental impact on offspring health

Whole genome sequencing can improve clinical care of childhood cancer

Whole genome sequencing can improve clinical care of childhood cancer

Hesse's LOEWE program supports cutting-edge CAR-T cell therapy research

Hesse's LOEWE program supports cutting-edge CAR-T cell therapy research

Targeted gene therapy may reduce AML burden and protect the heart from cardiotoxicity

Targeted gene therapy may reduce AML burden and protect the heart from cardiotoxicity

Regular IgG monitoring and replacement therapy reduce severe infections in CLL and NHL patients

Regular IgG monitoring and replacement therapy reduce severe infections in CLL and NHL patients

Artificial variants of Withanolides act highly specifically against leukemia cells

Artificial variants of Withanolides act highly specifically against leukemia cells

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.